Research programme: psychedelic and empathogenic compounds - MindMed/MindShift Compounds
Latest Information Update: 28 Mar 2025
At a glance
- Originator MindShift Compounds
- Class Drug withdrawal therapies; Ergolines; Neuropsychotherapeutics; Phenethylamines; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Mental disorders; Substance-related disorders
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for research development in Mental-disorders in Switzerland
- 28 Mar 2025 No recent reports of development identified for research development in Mental-disorders in USA
- 28 Mar 2025 No recent reports of development identified for research development in Substance-related disorders in Switzerland